Omeros (OMER) said late Wednesday it has submitted a briefing package to the US Food and Drug Administration after the agency raised concerns about...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Omeros Corp. (OMER) said Thursday it has closed the sale of Omidria eye medication to Rayner Surgical in a deal valued in excess of $1 billion. The...
Health care stocks were ending off Thursday's pace, with the NYSE Health Care Index rising 0.5% this afternoon while the SPDR Health Care Select Sector ETF...
| Address | The Omeros Building Seattle, Washington 98119 |
| Phone | +1 206 676-5000 |
| Number of Employees | 236 |
| Recent SEC Filing | 12/30/2021 8-K |
| Chairman, President & Chief Executive Officer | Gregory A. Demopulos |
| Chief Financial Officer, Treasurer & VP | Michael A. Jacobsen |
| Chief Scientific Officer & Vice President-Science | George A. Gaitanaris |
| Chief Medical Officer & Vice President | J. Steven Whitaker |
| Price Open | $5.24 |
| Previous Close | $5.35 |
| 52 Week Range | $5.02 - 23.85 |
| Market Capitalization | $331.5 M |
| Shares Outstanding | 62.5 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 03/07/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$1.99 |
| Beta vs. S&P 500 | N/A |
| Revenue | $29.9 M |
| Net Profit Margin | -136.61% |
| Return on Equity | 58.08% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
